GA-TSYS
12.9.2019 14:02:03 CEST | Business Wire | Press release
TSYS (NYSE: TSS) today announced a new authentication product that provides unprecedented real-time verification of customer identities. The new offering, the TSYS Authentication PlatformSM , relies on customer experience data collected from direct cardholder touchpoints and integrates into TSYS clients’ existing authentication systems. TSYS Authentication Platform is available in Europe and will be launched in North America in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005131/en/
The new product is designed to verify that a person is who he or she claims to be, reducing application, transaction and account takeover fraud, while still providing a frictionless customer experience. It’s effective at combatting synthetic identity fraud because it does not rely on reported data, which inherently creates inefficient lag time in the verification process.
The platform utilizes the latest technology – including machine learning – to provide real-time, informed opinions about any type of remote customer interaction or transaction with a financial institution for both consumer and commercial relationships. Examples include originating an account, updating a customer profile, changing a password or making a purchase.
TSYS can provide unparalleled cross-issuer and cross-border insight thanks to its relationships with more than 130 card issuers worldwide.
“At TSYS, we understand how various transactions are connected because we work with a global network of card issuers representing millions of individual accounts,” said Justin Griggs, senior vice president of product strategy and commercialization, TSYS Issuer Solutions. “If a device has been compromised in Ireland, for example, we can use that information to flag a remote login attempt in North America. We have real-time knowledge of potential fraud issues, and now we’re using that information to help our clients authenticate their customers and transactions across any use case.”
The TSYS Authentication Platform aids TSYS customers with their compliance needs to align with the European Union’s Payment Service Directive 2 (PSD2) and Strong Customer Authentication (SCA) provision by providing the ability to flexibly keep pace with the rapidly evolving world of authentication.
TSYS partnered with four key companies to develop the product:
- Featurespace , the leading provider of the award-wining, scalable ARIC™ platform and inventor of Adaptive Behavioral Analytics, previously collaborated with TSYS on the TSYS Foresight Score SM transaction fraud product. The new Authentication Platform utilizes Featurespace’s flexible multi-tenant capabilities that enables an industry-wide view of new fraud vectors for advanced decisioning.
- Emailage is a global leader in online fraud prevention and email risk assessment. Emailage’s technology leverages email address metadata, state of the art machine learning and dynamic data from a global network to generate multi-dimensional identity profiles and render a fraud risk score. This helps users build better informed fraud decision making processes.
- InAuth is a leading digital device intelligence company that specializes in using browser and app information to authenticate online transactions. It will ensure that TSYS clients know and understand the trustworthiness of every device interacting with their digital channels, including mobile app, mobile web and desktop.
- Payfone is the leading digital identity authentication network for the connected world. Their solutions enable consumers and businesses to transact with trust across all channels. Payfone can improve “pass rates” while thwarting synthetic IDs and identity theft with real-time, passive authentication and predictive identity confidence through their proprietary Trust Score™. They will measure the potential risk associated with a digital identity, so users can trust they know who their customers are.
TSYS will continue to enhance its authentication measures to help combat the fraud landscape and expects to leverage additional functionality such as facial recognition, document scanning, and behavioral biometrics, as well as utilize differentiated data sets through 2020 and beyond.
For more information about the TSYS Authentication Platform visit https://www.tsys.com/authentication-platform
About TSYS
TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — for issuers, merchants and consumers. We succeed because we put people and their needs at the heart of every decision to help them unlock payment opportunities. It’s an approach we call People-Centered Payments® .
Our headquarters are located in Columbus, Ga., U.S.A., with approximately 13,000 team members and local offices across 13 countries. TSYS generated revenue of $4.0 billion in 2018, while processing more than 32.3 billion transactions. We are a member of The Civic 50 and were named one of the 2018 World's Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
